Texas Equine Veterinary Association

www.teva-online.org • Page 17 beneficial for treatment of septic arthritis or osteomyelitis from the carpus or tarsus distally; regional limb perfusion yields a comparable response and is much easier to perform in comparison to intraosseous perfusion. Intraosseous perfusion can intra- articular infusion of antimicrobials achieve 100x the minimal inhibitory concentrations (MIC) whereas regional limb perfusion achieves similar intra-articular concentrations while achieving 30x MIC in the surrounding tissues. Continuous rate infusion of antimicrobials into septic synovial structures has proven to be beneficial treatment for septic arthritis. Sustained release antimicrobial gels have also shown clinical value for treatment of septic arthritis, septic tenosynovitis, and osteomyelitis. Surgical debridement of osteomyelitis is usually reserved for cortical bone distant from a physis or joint. Debridement of a septic physis may result in instability, potentiate pathologic fractures, and result in angular limb deformities; physeal debridement is generally not performed. Chondroprotective agents may be beneficial in restoring and maintaining joint health. Hyperbaric oxygen therapy for Submitted by TEVA Member: John C. Janicek, DVM, MS, DACVS Brazos Valley Equine Hospital, Navasota, TX 77868 936-825-2197 | jcjanicek@yahoo.com NO GENERIC ADEQUAN ® Get the facts at www.nogenericadequan.com There is BRIEF SUMMARY : Adequan ® i.m.: For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. There are no known contraindications to the use of intramuscular Adequan ® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. Each 5 mL contains 500 mg Polysulfated Glycosaminoglycan. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Adequan ® I.A.: For the intra-articular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Inflammatory joint reactions and septic arthritis have been reported following administration of Adequan ® I.A. Joint sepsis, a rare but potentially life threatening complication, can occur after intra-articular injection. Use only in the carpal joint of horses. Each 1 mL contains 250 mg Polysulfated Glycosaminoglycan. WARNING: Do not use in horses intended for human consumption. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. SEE PRODUCT PACKAGE INSERTS FOR FULL PRESCRIBING INFORMATION. Adequan ® is a registered trademark of Luitpold Pharmaceuticals, Inc. ©LUITPOLD PHARMACEUTICALS, INC., Animal Health Division, Shirley, NY 11967. AHD 010, Rev. 1/2014 treatment of osteomyelitis has shown beneficial revascularization of ischemic tissues and increasing the effectiveness of antimicrobial therapy. The prognosis for foals with septic arthritis or osteomyelitis is favorable, but ultimately depends upon an early diagnosis and treatment, infection location, and antimicrobial susceptibility. It is difficult to prognosticate the outcome of these cases. In general, foals treated early for septic arthritis can have a good prognosis for full recovery; foals with an articular infection involving subchondral bone have a poor prognosis. Foals with focal osseous lesions involving only the physis and no bone instability can have a good prognosis. Those with pathologic fracture or severe angular limb deformities have a poor prognosis and may be candidates for humane destruction. Multiple sites of involvement have a detrimental effect on survival and athleticism. We ARe cuRRentLY AccePtIng suBmIssIons foR ouR 2014 teXAs tAKes. TEXAS TAKES are 15-minute practical scientific presentations presented by our TEVA members at the Symposium. Presentations can include: interesting case series, scientific studies, review articles, "How-tos", and evidence-based clinical questions. We are looking for practical information Texas and regional veterinarians can use every day. We welcome submissions from interns, residents, academics and private practitioners. TEVA needs your knowledge and experience to make this year's Summer Symposium better than ever! Please do not let the format (described below) scare you. It is not as hard as it looks, and if you need help with the format or presentation set up, we have mentors available who are ready and willing to advise you. The deadline for paper submission will be June 1, 2014. Please read on for instructions on how to become a part of this dynamic new panel series. The wining presentation will receive an iPad! suBmIssIon guIDeLInes • Include primary author address, phone, fax and email address. • No fewer than 250 words; no word maximum • 12-point Times New Roman font • Pictures/Diagrams are encouraged, especially for "How to" presentations. • Headings should include: Take Home Message, Introduction Materials and Methods, Results, Discussion, References • Titles should be 15 words or fewer If you have questions, please contact "texas takes" chairman, Dr. Jake hersman. email: jakehersman@yahoo.com. t e X A S t A K e S

• Cover